SAGE Therapeutics, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für SAGE Therapeutics, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um SAGE Therapeutics, Inc. zu Deinem Portfolio hinzuzufügen.
NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / May 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.